Is vaccine the magic bullet for malaria elimination? A reality check

Malaria Journal

Volumn 9, Issue SUPPL. 3, 2010, Pages

  Chilengi, Roma ^a,b   Gitaka, Jesse ^a  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; ATOVAQUONE PLUS PROGUANIL; ERYTHROCYTE MEMBRANE PROTEIN 1; FANSIMEF; INSECT REPELLENT; MALARIA VACCINE; PYRIMETHAMINE PLUS SULFADOXINE;

DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; MALARIA; MALARIA CONTROL; MORBIDITY; MORTALITY; PARASITE VECTOR; REVIEW; IMMUNOLOGY; METHODOLOGY; MOSQUITO; UTILIZATION REVIEW; VACCINATION;

ANTIMALARIALS; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; MALARIA; MALARIA VACCINES; MOSQUITO CONTROL; VACCINATION;

EID: 78650471456     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-S1-S1     Document Type: Review

References (62)

1. Malaria: progress, perils, and prospects for eradication. BM Greenwood DA Fidock DE Kyle SHI Kappe PL Alonso, J Clin Invest 2008 118 1266 1276 10.1172/JCI33996 18382739
2. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. KI Barnes DN Durrheim F Little A Jackson U Mehta E Allen SS Dlamini J Tsoka B Bredenkamp DJ Mthembu NJ White BL Sharp, PLoS Med 2005 2 330 10.1371/journal.pmed.0020330 16187798
3. A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. PM Nyarango T Gebremeskel G Mebrahtu J Mufundu U Abdulmumini A Ogbamariam A Kosia A Gebremichael D Gunawardena Y Ghebrat Y Okbaldet, Malar J 2006 5 33 10.1186/1475-2875-5-33 16635265
4. Impact of artemisinin based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. A Bhattarai SA Abdullah SP Kachur A Martensson AK Abbas R Khatib A Abdul M Ramsan G Rotllant JF Gerstenmaier F Molteni S Abdulla SM Montgomery A Kaneko A Bjorkman, PLoS Med 2007 4 309 10.1371/journal.pmed.0040309 17988171
5. The global distribution of clinical episodes of Plasmodium falciparum malaria. RW Snow CA Guerra AM Noor HY Myint SI Hay, Nature 2005 434 214 217 10.1038/nature03342 15759000
6. Malaria. BM Greenwood K Bojang CJM Whitty GAT Targett, Lancet 2005 365 1487 1498 10.1016/S0140-6736(05)66420-3 15850634
7. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. RW Snow M Craig U Deichmann K Marsh, Bull World Health Organ 1999 77 624 640 10516785
8. Progress and challenges for malaria vaccines. TL Richie A Saul, Nature 2002 415 694 701 10.1038/415694a 11832958
9. Do we still need a malaria vaccine? B Greenwood G Targett, Parasite Immunol 2009 31 582 586 10.1111/j.1365-3024.2009.01140.x 19691561
10. Malaria vaccines: research problems and priorities. D Arnot, http://www.scidev.net/en/health/malaria/policy-briefs/malaria-vaccines-research- problems-and-priorities.html Accessed 27th September 2010
11. Efficacy of RTS,S/AS01E Vaccine against malaria in children 5 to 17 months of age. P Bejon J Lusingu A Olotu A Leach M Lievens J Vekemans Johan Vekemans Mshamu Salum Lang Trudie Gould Jayne Dubois Marie-Claude Demoitié Marie-Ange Stallaert Jean-Francois Vansadia Preeti Carter Terrell Njuguna Patricia Awuondo O. Ken Malabeja Anangisye Abdul Omar Gesase Samwel Mturi Neema Drakeley J. Chris Savarese Barbara Villafana Tonya W Ripley Ballou Cohen Joe Riley M. Eleanor Lemnge M. Martha Marsh Kevin von Seidlein Lorenz, N Engl J Med 2008 359 2521 32 10.1056/NEJMoa0807381 19064627
12. Informal consultation on malaria elimination: setting up the WHO agenda. WHO, WHO/HTM/MAL/2006/.1114
13. Eradicating malaria: high hopes or a tangible goal? I Brito, Health Policy at Harvard 2001 2 61 66
14. Malaria control, achievements, problems and strategies. JA Najera, (WHO document No. MAL/99.1087)
15. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. CV Plowe P Alonso SL Hoffman, J Infect Dis 2009 200 1646 1649 10.1086/646613 19877844
16. Revisiting the basic reproductive number for malaria and its implications for malaria control. DL Smith FE McKenzie RW Snow SI Hay, PLoS Biol 2007 5 42 10.1371/journal.pbio.0050042 17311470
17. Pre-erythrocytic malaria vaccines: towards greater efficacy. AVS Hill, Nature Reviews 2006 6 21 32 10.1038/nri1746 16493425
18. High road, low road? Choices and challenges on the pathway to a malaria vaccine. T Richie, Parasitology 2006 133 Suppl. 113 S144 10.1017/ S0031182006001843 17274843
19. Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria. M Walther, Expert Review Vaccines 2006 5 81 93 10.1586/14760584.5.1.81
20. th March 2010
21. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. SL Hoffman LM Goh TC Luke I Schneider TP Le DL Doolan J Sacci P Vega M Dowler C Paul DM Gordon JA Stoute LWP Church M Sedegah DG Heppner WR Ballou TL Richie, J Infect Dis 2002 185 1155 1164 10.1086/339409 11930326
22. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies 1971-75. DS Clyde, Bull World Health Organ 1990 68 9 12 2094597
23. Effect of expanded insecticide treated bednet coverage on child survival in rural Kenya: a longitudinal study. GW Fegan AM Noor WS Akhwale S Cousens RW Snow, Lancet 2007 370 1035 1039 10.1016/S0140-6736(07)61477-9 17889242
24. Mortality and morbidity from malaria in Gambian children after introduction of an impregnated bed net programme. U DAlessandro B Olaleye P Langerock MK Aikins MC Thomson MK Cham BM Greenwood W McGuire S Bennett MK Cham BA Cham, Lancet 1995 345 479 483 10.1016/S0140-6736(95)90582-0 7861874
25. Effect of large-scale social marketing of insecticide-treated nets on child survival in rural Tanzania. JR Schellenberg S Abdulla R Nathan O Mukasa TJ Marchant N Kikumbih AK Mushi H Mponda H Minja H Mshinda M Tanner C Lengeler, Lancet 2001 357 1241 1247 10.1016/S0140-6736(00)04404-4 11418148
26. A low-cost repellent for malaria vectors in the Americas: results of two field trials in Guatemala and Peru. SJ Moore ST Darling M Sihuincha N Padilla GJ Devine, Malar J 2007 6 101 10.1186/1475-2875-6-101 17678537
27. Comparative efficacy of insect repellents against mosquito bites. MS Fradin JF Day, N Engl J Med 2002 347 13 18 10.1056/NEJMoa011699 12097535
28. Indoor residual spraying for preventing malaria. B Pluess FC Tanser C Lengeler BL Sharp, Cochrane Database of Systematic Reviews 2010 Issue 4 Art.No.:CD006657
29. Community-wide benefits of targeted indoor residual spray for malaria control in the Western Kenya Highland. G Zhou AK Githeko N Minakawa G Yan, Malar J 2010 9 67 10.1186/1475-2875-9-67 20199674
30. Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants. A Ross M Penny N Maire A Studer I Carneiro D Schellenberg B Greenwood M Tanner T Smith, PLoS ONE 2008 3 2661 10.1371/journal.pone.0002661 18628828
31. Intermittent preventive treatment against malaria in infants in Gabona randomized, double-blind, placebo-controlled trial. MP Grobusch B Lell NG Schwarz J Gabor J Dörnemann M Pötschke S Oyakhirome GC Kiessling M Necek MU Längin PK Klouwenberg A Klöpfer B Naumann H Altun ST Agnandji J Goesch M Decker CLO Salazar C Supan DU Kombila L Borchert L Köster P Pongratz AA Adegnika IV Glasenapp S Issifou PG Kremsner, J Infect Dis 2007 196 1595 1602 10.1086/522160 18008242
32. Effectiveness of combined intermittent preventive treatment for children and timely home treatment for malaria control. CK Ahorlu KA Koram AK Seakey MG Weiss, Malar J 2009 8 292 10.1186/1475-2875-8-292 20003357
33. Specificities of antibodies that inhibit merozoite dispersal from malaria-infected erythrocytes. JA Lyon AW Thomas T Hall JD Chulay, Mol Biochem Parasitol 1989 36 77 85 10.1016/0166-6851(89)90203-X 2509909
34. A robust neutralization test for Plasmodium falciparum malaria. A Saul LH Miller, J Exp Med 2001 193 51 54 10.1084/jem.193.12.F51 11136820
35. Measurement of Plasmodium falciparum growth rate in vivo: a test of malaria vaccines. Q Cheng G Lawrence C Reed A Stowers L Ranford-Cartwright A Creasey R Carter A Saul, Am J Trop Med Hyg 1997 57 495 500 9347970
36. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. H Bouharoun-Tayoun P Attanah A Sabchareon T Chongsuphajaisiddhi P Druilhe, J Exp Med 1990 172 1633 1641 10.1084/jem.172.6. 1633 2258697
37. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. H Bouharoun-Tayoun P Druilhe, Infect Immun 1992 60 1473 1481 1548071
38. The Glutamate-Rich Protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. M Theisen S Soe C Oeuvray A Thomas J Vuust S Denielsen S Jepsen P Druile, Infect Immun 1998 66 11 17 9423833
39. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. B Genton I Betuela I Felger F Al-Yaman RF Anders A Saul L Rare M Baisor K Lorry GV Brown D Pye DO Irving TA Smith HP Beck MP Alpers, J Infect Dis 2002 185 820 827 10.1086/339342 11920300
40. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. ME Polhemus AJ Magill JF Cummings KE Kester CF Ockenhouse DE Lanar S Dutta A Barbosa L Soisson CL Diggs SA Robinson JD Haynes AV Stewart LA Ware C Brando U Krzych RA Bowden JD Cohen MC Dubois OA Opokua, Vaccine 2007 25 4203 4212 10.1016/j.vaccine.2007.03.012 17442466
41. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a phase 1 randomized controlled trial. MA Thera OK Doumbo D Coulibaly DA Diallo AK Kone AB Guindo K Traore M Sissoko DA Diallo I Diarra B Kouiba M Daou A Dolo M Baby MS Sissoko I Sagara A Niangaly I Traore SI Diawara A Owusu JN Nixon A Gregson E Angov VA Stewart O Godeaux A Leach MC Dubois WR Bollou J Cohen D Thomson T Dube L Soisson CL Diggs SL Takala KE Lyke B House DE Lanar S Dutta DG Heppner CV Plowe, PLoS ONE 2008 3 1465 10.1371/journal.pone.0001465 18213374
42. Safety and Immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. MA Thera OK Doumbo D Coulibaly MB Laurens AK Kone AB Guindo K Traore M Sissoko DA Diallo I Diarra B Kouiba M Daou A Dolo M Baby MS Sissoko I Sagara A Niangaly I Traore A Olotu O Godeaux A Leach MC Dubois WR Bollou J Cohen D Thomson T Dube L Soisson CL Diggs SL Takala KE Lyke B House DE Lanar S Dutta DG Heppner CV Plowe, PLoS ONE 2010 5 9041 10.1371/journal.pone.0009041 20140214
43. Malaria vaccines and their potential role in the elimination of malaria. GA Targett BM Greenwood, Malar J 2008 7 Suppl 1 10 10.1186/1475-2875-7-S1-S10 19091034
44. Early treatment of childhood fevers with pre-packaged antimalarial drugs in the home reduces severe malaria morbidity in Burkina Faso. SB Sirima A Konaté AB Tiono N Convelbo S Cousens F Pagnoni, Tropical Medicine & International Health 2003 8 133 139 10.1046/j.1365-3156.2003.00997.x (Pubitemid 36269364)
45. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. PJ Guerin P Olliaro F Nosten P Druilhe R Laxminarayan F Binka WL Kilama N Ford NJ White, Lancet Infect Dis 2002 2 564 573 10.1016/S1473-3099(02)00372-9 12206972 (Pubitemid 34966359)
46. Increased gametocytemia after treatment: An early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. BI Karen F Little A Mabuza N Mngomezulu J Govere D Durrheim C Roper B Watkins NJ White, J Infect Dis 2008 197 1605 1613 10.1086/587645 18471066
47. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. DR Chowdhury E Angov T Kariuki N Kumar, PLoS ONE 2009 4 6352 10.1371/journal.pone.0006352 19623257
48. Transmission blocking malaria vaccines. R Carter, Vaccine 2001 19 2309 2314 10.1016/S0264-410X(00)00521-1 11257353
49. Malaria transmission-blocking vaccineshow can their development be supported? R Carter KN Mendis LH Miller L Molineaux A Saul, Nature Med 2000 6 241 244 10.1038/73062 10700212
50. Reducing Plasmodium falciparum malaria transmission in africa: a model-based evaluation of intervention strategies. JT Griffin TD Hollingsworth LC Okell TS Churcher M White, PLoS Med 2010 7 1000324 10.1371/journal.pmed. 1000324 20711482
51. Clinical development of malaria vaccines: should earlier trials be done in malaria endemic countries? R Chilengi, Human Vaccines 2009 5 9 1 10
52. Spatial and temporal variation in malaria transmission in a low endemicity area in northern Tanzania. MJAM Oesterholt JT Bousema OK Mwerinde C Harris P Lushino A Masokoto H Mwerinde FW Mosha CJ Drakeley, Malar J 2006 5 98 10.1186/1475-2875-5-98 17081311
53. The impact of IPTi and IPTc interventions on malaria clinical burden - in silico perspectives. R Águas JML Lourenço GMM Gomes LJ White, PLoS ONE 2009 4 6627 10.1371/journal.pone.0006627 19675675
54. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. PL Alonso J Sacarlal JJ Aponte A Leach E Macete J Milman I Mandomando B Spiessens C Guinovart M Espasa Q Bassat P Aide O Ofori-Anyinam MM Navia S Corachan M Ceuppens M Dubois MA Demoitié F Dubovsky C Menéndez N Tornieporth WR Ballou R Thompson J Cohen, Lancet 2004 364 1411 20 10.1016/S0140-6736(04) 17223-1 15488216
55. th March 2010
56. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. AA Amin D Zurovac BB Kangwana J Greenfield DN Otieno WS Akhwale RW Snow, Malar J 2007 6 72 10.1186/1475-2875-6- 72 17535417
57. The global health system: actors, norms, and expectations in transition. NA Szlezak BR Bloom DT Jamison GT Keusch CM Michaud S Moon WC Clark, PLoS Medicine 2010 7 1000183 10.1371/journal.pmed.1000183 20052277
58. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. AD Lopez CD Mathers M Ezzati DT Jamison CJ Murray, Lancet 2006 367 1747 1757 10.1016/S0140-6736(06)68770-9 16731270
59. The malaria atlas project: developing global maps of malaria risk. SI Hay RW Snow, PLoS Med 2006 3 473 10.1371/journal.pmed.0030473 17147467
60. Disease control priorities in developing countries. DT Jamison JG Breman AR Measham G Alleyne M Claeson, World Bank Publications 2007 1352
61. Prevention of chronic diseases: A call to action. R Beaglehole S Ebrahim S Reddy, Lancet 2007 370 2152 2157 10.1016/S0140-6736(07)61700-0 18063026
62. Interactions between malaria parasites infecting the same vertebrate host. TL Richie, Parasitology 1988 96 pt 3 607 39 10.1017/S0031182000080227 3043327